Analyst Price Targets — BCAX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 18, 2026 8:20 pm | — | BMO Capital | $35.00 | $24.92 | TheFly | Bicara Therapeutics initiated with an Outperform at BMO Capital |
| August 12, 2026 11:55 am | — | Wedbush | $33.00 | $23.76 | TheFly | Bicara Therapeutics price target raised to $33 from $30 at Wedbush |
| August 12, 2026 11:08 am | — | BTIG | $39.00 | $23.76 | TheFly | Bicara Therapeutics price target raised to $39 from $28 at BTIG |
| August 12, 2026 10:36 am | Joseph Catanzaro | Mizuho Securities | $20.00 | $23.76 | StreetInsider | Bicara Therapeutics Inc (BCAX) PT Raised to $20 at Mizuho |
| August 12, 2026 10:27 am | — | Goldman Sachs | $20.00 | $23.76 | TheFly | Bicara Therapeutics price target raised to $20 from $18 at Goldman Sachs |
| August 11, 2026 5:37 pm | Judah Frommer | Morgan Stanley | $39.00 | $23.76 | StreetInsider | Bicara Therapeutics Inc (BCAX) PT Raised to $39 at Morgan Stanley |
| May 12, 2026 12:06 pm | — | Morgan Stanley | $37.00 | $22.38 | TheFly | Bicara Therapeutics price target raised to $37 from $36 at Morgan Stanley |
| May 12, 2026 10:47 am | — | Goldman Sachs | $18.00 | $22.92 | TheFly | Bicara Therapeutics price target raised to $18 from $16 at Goldman Sachs |
| May 11, 2026 12:42 am | — | Guggenheim | $42.00 | $22.58 | TheFly | Bicara Therapeutics initiated with a Buy at Guggenheim |
| February 11, 2026 9:42 pm | Richard Law | Goldman Sachs | $14.00 | $14.80 | TheFly | Bicara moved to Neutral from Early-Stage Biotech at Goldman Sachs |
Latest News for BCAX
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara's 2026 Inducement Plan as a material inducement to her commencement of employment as…
Dimensional Fund Advisors LP grew its holdings in Bicara Therapeutics Inc. (NASDAQ: BCAX) by 166.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,261 shares of the company's stock after purchasing an additional 68,327 shares during the quarter. Dimensional
Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort size warrant caution ahead of pivotal phase 3 readout. Strong cash position ($500M liquidity) supports operations into 2029, enabling pursuit of interim phase 3 results and potential commercialization.
Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BCAX.
U.S. House Trading
No House trades found for BCAX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.